Modulation of Staphylococcus aureus Biofilm Matrix by Subinhibitory Concentrations of Clindamycin

Antimicrob Agents Chemother. 2016 Sep 23;60(10):5957-67. doi: 10.1128/AAC.00463-16. Print 2016 Oct.

Abstract

Staphylococcus aureus biofilms are extremely difficult to treat. They provide a protected niche for the bacteria, rendering them highly recalcitrant toward host defenses as well as antibiotic treatment. Bacteria within a biofilm are shielded from the immune system by the formation of an extracellular polymeric matrix, composed of polysaccharides, extracellular DNA (eDNA), and proteins. Many antibiotics do not readily penetrate biofilms, resulting in the presence of subinhibitory concentrations of antibiotics. Here, we show that subinhibitory concentrations of clindamycin triggered a transcriptional stress response in S. aureus via the alternative sigma factor B (σ(B)) and upregulated the expression of the major biofilm-associated genes atlA, lrgA, agrA, the psm genes, fnbA, and fnbB Our data suggest that subinhibitory concentrations of clindamycin alter the ability of S. aureus to form biofilms and shift the composition of the biofilm matrix toward higher eDNA content. An understanding of the molecular mechanisms underlying biofilm assembly and dispersal in response to subinhibitory concentrations of clinically relevant antibiotics such as clindamycin is critical to further optimize antibiotic treatment strategies of biofilm-associated S. aureus infections.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / pharmacology*
  • Biofilms / drug effects
  • Clindamycin / administration & dosage
  • Clindamycin / pharmacology*
  • Dose-Response Relationship, Drug
  • Extracellular Matrix / drug effects
  • Extracellular Matrix / genetics
  • Gene Expression Regulation, Bacterial / drug effects
  • Humans
  • Mutation
  • Staphylococcus aureus / drug effects*
  • Staphylococcus aureus / isolation & purification
  • Staphylococcus aureus / physiology

Substances

  • Anti-Bacterial Agents
  • Clindamycin

Grants and funding

This work was supported by grants from the Swiss National Science Foundation (310030_146295/1 to A.S.Z.), the Hartmann Müller-Stiftung (to A.S.Z.), and the Promedica Stiftung (1080/A to B.H.).